LincRNA00892 also has been reported possibly activated CD4+ T and B cells by targeting heterogeneous nuclear ribonucleoprotein K (hnRNP K) and subsequently up-regulating the expression of CD40L, thereby playing a pathogenic role in SLE (63). Here, HNRNPK is linked to systemic lupus erythematosus.